Coronary Stents Market is Expected to Witness a Steady Growth by 2026

Future Market Insights provides an in-depth analysis of the global coronary stents market in a new report titled “Coronary Stents Market: Global Industry Analysis and Opportunity Assessment, 2016-2026”. Coronary stents is a billion dollars industry that occupies a significant market share in the cardiovascular market. In terms of revenue, the global coronary stents market is estimated to reach a market valuation of US$ 6,002.9 Mn by 2016 end and is expected to register a CAGR of 6.6% during the forecast period. The global coronary stents market is expected to represent incremental opportunity of US$ 5,318.7 Mn between 2016 and 2026.

According to Future Market Insights, factors such as an increase in the prevalence of coronary artery disease, obesity, and minimal invasive procedures; and an increasing preference for advanced stenting procedures by cardiologists are some of the factors fuelling the growth of the global coronary stents market. Economic factors such as an increase in awareness campaigns about cardiovascular diseases conducted by government bodies, rapid progress in medical technology, and extended reimbursement support are also expected to boost the growth of the global coronary stents market over the forecast period.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1993 

Segmentation highlights

The global coronary stents market is segmented on the basis of Product Type (Drug Eluting Stent, Bare Metal Stent, Bioresorbable Vascular Stent); Raw Material (Cobalt Chromium, Stainless Steel, Platinum-Chromium, Nickel-Titanium, Polymer); and End Use (Hospitals, Ambulatory Surgical Centres, Cardiac Catheterisation Laboratories).

• The Drug Eluting Stent product type segment is estimated to be valued at US$ 8,750.2 Mn by 2026. The Bioresorbable Vascular Stent segment is estimated to account for 11.0% revenue share by 2016 end
• The Polymer raw material segment is estimated to account for the highest market share of 29.2% by the end of 2016. The Cobalt Chromium segment is expected to register a CAGR of 5.6% during the forecast period
• The Hospitals end use segment is anticipated to account for 70.9% value share of the global coronary stents market by the end of 2016. The Cardiac Catheterisation Laboratories segment is estimated to be valued at US$ 2,526.8 Mn by the end of 2026, registering a CAGR of 8.0% over the forecast period

Regional projections

The global coronary stents market is segmented on the basis of region into North America, Latin America, Western Europe, Eastern Europe, APEJ, MEA, and Japan. The APEJ market is estimated to be valued at US$ 4,165.2 Mn by 2026, exhibiting a CAGR of 8% during the forecast period. The North America coronary stents market is expected to dominate the global coronary stents market in terms of revenue by 2016 end and is likely to retain its dominance throughout the forecast period. The coronary stents market in North America is estimated to account for 29.2% market share of the global coronary stents market by 2016 end. The North America region is likely to be the second most attractive market with an attractiveness index of 2.5 during the forecast period. The markets in North America, Western Europe, and APEJ represent the highest growth opportunities in the global coronary stents market owing to a large patient population and an increasing demand for coronary stents in these regions.

Need more information about Report methodology ? @ https://www.futuremarketinsights.com/askus/rep-gb-1993 

Vendor insights

The global coronary stents market report profiles some of the top companies operating in the market. Leading market players featured in the report include Terumo Corporation, Boston Scientific Corporation, Medtronic, Vascular Concepts, B. Braun Melsungen AG, Biotronik SE & Co. KG, Abbott Laboratories, Biosensors International Group, Ltd., Hexacath, and Stentys SA. Key market players are focussing on increasing their footprints in emerging markets such as Asia Pacific and are expanding their manufacturing facilities and distribution network to gain a larger share of the global coronary stents market.

Positron Emission Tomography (PET) Scanners Market - Global Industry Analysis by 2026

Future Market Insights delivers key insights on the global Positron Emission Tomography scanners marketin a new report titled, “Positron Emission Tomography (PET) Scanners Market: Global Industry Analysis and Opportunity Assessment, 2016–2026”. In terms of revenue, the global Positron Emission Tomography (PET) scanners market is projected to register a healthy CAGR of 4.7% over the forecast period.

According to Future Market Insights, growing occurrences of chronic disorders and increasing penetration of PET machines is expected to drive overall growth of the global Positron Emission Tomography (PET) scanners market during the forecast period. Rising demand for effective diagnostic techniques across the globe and expanded applications for PET in the field of oncology are further expected to boost the growth of the global Positron Emission Tomography (PET) scanners market between 2016 and 2026. However, a short half-life and low supply of radiopharmaceuticals is likely to restrict market growth over the forecast period. 

“A key trend in the global Positron Emission Tomography (PET) scanners market is the development of dual modality PET/CT and PET/MRI machines leading to better diagnostic sensitivity and specificity at each stage of disease prognosis. The entry of new radiopharmaceuticals has enhanced the diagnostic value of diseases treatment resulting in greater dependency on PET scanning procedures. These trends are likely to govern the global Positron Emission Tomography (PET) scanners market in the coming years.” - Analyst - Healthcare, Pharmaceuticals & Medical Devices, Future Market Insights

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-1333

Segmentation highlights

The global Positron Emission Tomography (PET) scanners market has been segmented by Product Type (Full Ring PET Scanners, Partial Ring PET Scanners); by Application (Oncology, Cardiology, Neurology, Others); by Detector Type (Bismuth Germanium Oxide (BGO), Lutetium Oxyorthosilicate (LSO), Gadolinium Oxyorthosilicate (GSO), Lutetium Fine Silicate (LFS), Lutetium Yttrium Orthosilicate); and by End User (Hospitals, Diagnostic Centres, PET Centres, Research Institutes);

• The Full Ring PET Scanners product type segment was valued at US$ 759.3 Mn in 2015 and is expected to register 4.8% CAGR over the forecast period. The Partial Ring PET Scanners product type segment was valued at US$ 143.8 Mn in 2015 and is expected to increase to US$ 212.2 Mn by the end of 2026
• The Oncology application segment is estimated to account for 86.6% market share by 2016 while the Cardiology application segment is estimated to account for 5.0% market share by 2016 end. Both these segments are expected to be the most lucrative segments in the global Positron Emission Tomography (PET) scanners market during the forecast period
• The Lutetium Oxyorthosilicate (LSO) detector type segment was valued at US$ 322.7 Mn in 2015 and is expected to witness a CAGR of 4.3% over the forecast period to reach US$ 596.5 Mn by 2026 end. The Bismuth Germanium Oxide (BGO) detector type segment was valued at US$ 266.7 Mn in 2015 and is expected to increase to US$ 400.5 Mn by the end of 2026
• The Hospitals end user segment is estimated to hold 35.7% market share by 2016 end while the Diagnostic Centres end user segment is estimated to account for 33.0% market share by 2016 end

Regional market projections

The global Positron Emission Tomography (PET) scanners market has been segmented into the seven key regions of North America, Latin America, Western Europe, Eastern Europe, APEJ, MEA, and Japan. North America dominated the global Positron Emission Tomography (PET) scanners market in 2015 and is likely to continue its dominance throughout the forecast period. North America is expected to reach a market valuation of US$ 631.9 Mn by 2026 end, witnessing a CAGR of 4.8% over the forecast period. The APEJ Positron Emission Tomography (PET) scanners market is estimated to be valued at US$ 132.9 Mn by 2016 end and is expected to register a CAGR of 5.1% over the forecast period.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-1333

Vendor insights

General Electric Co., Toshiba Corporation, Koninklijke Philips N.V., Siemens AG, Hitachi, Ltd., Positron Corporation, Mediso Ltd., and Yangzhou Kindsway Biotech Co. Ltd. are some of the leading players operating in the global Positron Emission Tomography (PET) scanners market. Major players in the global Positron Emission Tomography (PET) scanners market are focussing on enhancing their global and regional presence through introduction of novel products and strategic operational expansion. The report discusses individual strategies followed by these companies in terms of enhancing product designing, creating new manufacturing facilities, market consolidation, and advanced R&D initiatives.

Orthopaedic Bone Cement and Casting Materials Market Rugged Expansion Foreseen by 2027

In a recent global market study, the analysts of Future Market Insights examined the various factors impacting revenue growth of the global orthopaedic bone cement and casting materials market. An increasing prevalence of orthopaedic disorders and patient preference towards quality treatment for a better lifestyle are primarily responsible for fuelling market demand for orthopaedic bone cement and casting materials. The analysts have presented their forecasts along with the key market dynamics including revenue drivers, growth restraints, and market opportunities and trends in a new publication titled “Orthopaedic Bone Cement and Casting Materials Market: Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027” that presents detailed forecasts of the global orthopaedic bone cement and casting materials market for a period of 10 years (2017 – 2027) by benchmarking the historical market estimations from 2012 to 2016.

Factors Impacting Revenue Growth of the Global Orthopaedic Bone Cement and Casting Materials Market

Future Market Insights analysis reveals the various factors that are likely to boost the growth in adoption of orthopaedic bone cement and casting materials. A growing number of people suffering from bone diseases such as osteoporosis, an increasing number of sports injuries and accidents leading to fractures of the bone, and the availability of advanced treatment options for severe back pain are some of the factors likely to drive the market towards high revenue growth in the coming decade.

The global orthopaedic bone cement and casting materials market is also likely to witness a few trends in the near future. Growing research and development activities in the field of orthopaedics and increasing use of casting materials to treat orthopaedic injuries are expected to increase in the next few years, impacting the global market for orthopaedic bone cement and casting materials significantly.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4825 

Global Orthopaedic Bone Cement and Casting Materials Market: Regional Analysis & Forecast

Future Market Insights has tracked the performance of the global orthopaedic bone cement and casting materials market across the key geographies of North America, Latin America, Western Europe, Eastern Europe, Japan, APEJ, and MEA. Unsurprisingly, North America is the dominant regional market with estimated revenues in excess of US$ 1,400 Mn by the end of 2027, witnessing a CAGR of 5.1%. The APEJ orthopaedic bone cement and casting materials market is estimated to be valued at almost US$ 940 Mn by the end of 2027, recording an impressive CAGR of 9.7% – the highest among all the regional markets. The Western Europe regional market is slated to register a CAGR of 7.1% during 2017 – 2027.

Global Orthopaedic Bone Cement and Casting Materials Market: Segmental Forecasts

Forecast by Product Type: The global orthopaedic bone cement and casting materials market is segmented on the basis of product type into Bone Cement and Casting Materials. The Bone Cement segment is expected to be the most lucrative product type segment with an attractiveness index of 1.1 and a CAGR of 6.9% in terms of value.

Forecast by Application: The global orthopaedic bone cement and casting materials market is segmented on the basis of application into Joint Arthroplasty, Trauma Cases, Sports Injury, Spine Surgeries, and Others. Joint Arthroplasty is the most lucrative segment by application and also the largest, estimated to reach a market valuation of US$ 1,458.6 Mn by the end of 2027, registering a CAGR of 7.3%.

Forecast by End User: The global orthopaedic bone cement and casting materials market is segmented on the basis of end user into Hospitals, Ambulatory Surgical Centres, and Orthopaedic Clinics. Hospitals is the largest end user segment, estimated to reach a market valuation of just under US$ 2000 Mn and witness a growth rate of 7.0% between 2017 and 2027.

Global Orthopaedic Bone Cement and Casting Materials Market: Competitive Landscape

The report profiles some of the top companies operating in the global orthopaedic bone cement and casting materials market such as DJO Global, Inc., Heraeus Holding, Zimmer Biomet, BeneCare Medical, BSN medical, Stryker, 3M Health Care Ltd., DePuy Companies (Sub. Johnson & Johnson Services, Inc.), Smith & Nephew Plc, Exactech, Inc., Medtronic, Inc., B. Braun Melsungen AG, Cook Medical, SOMATEX® Medical Technologies GmbH, TEKNIMED, T-Tape Company B.V., Lohmann & Rauscher GmbH & Co. KG, MIKA MEDICAL, Össur, and Innovation Rehab LTD.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-4825 

Biopharmaceutical Contract Manufacturing Market: Opportunities, Demand and Forecasts, 2017-2027

A new study by FMI titled ‘Biopharmaceutical Contract Manufacturing Market: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027’, has listed out the key points being considered by Biopharmaceutical contract manufacturing companies to emerge and stay sustainably profitable in the long run. The North American Biopharmaceutical contract manufacturing market is expected to expand at a CAGR of close to 10%, and is expected to remain as a main sink market for revenues, as most of the biopharmaceutical contract manufacturing facilities are located in this region. Europe is expected to remain as the main source market for biopharmaceutical contract manufacturing services. However, with the increasing demand and availability of large sterile spaces required for biopharmaceutical contract manufacturing in countries such as China, the biopharmaceutical contract manufacturing market is witnessing a move to Asia, to countries such as China and South Korea.

The report finds that Biopharmaceutical contract manufacturing capacity is tight across the industry, regardless of the location. Globally, biopharma companies have spent over US$ 50 Bn in just the past five years on new plants and equipment. Much of that has been in tax havens like Ireland and Singapore, and in emerging markets. About a quarter of the projects have been in the U.S. There just aren’t enough facilities, and those that are available are too old for modern drugs. It takes nearly four years to design, build, and qualify a new plant. Large-scale plants can cost between US$ 1 Bn and US$ 2 Bn. Patheon’s recent acquisition of Roche’s small facility in biopharmaceutical contract manufacturing sector was attractive because it was inexpensive, but is far from the norm. Much of the ongoing capacity expansion in the biopharmaceutical contract manufacturing industry is customer-funded.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2982 

Biosimilar and biologics manufacturing are presenting strong growth opportunities for biopharmaceutical contract manufacturing organizations. The global biopharmaceutical contract manufacturing market is in a state of large consolidation, as participants in the biopharmaceutical contract manufacturing market look to inorganic growth strategies to offer integrated solutions to customers. For instance, leading players in biopharmaceutical contract manufacturing market – Patheon, Catalent, and AMRI have acquired IRIX Pharmaceuticals, Pharmatek, and Euticals, respectively. These biopharmaceutical contract manufacturing companies have been aggressive in expanding their products/services/capabilities through strategic alliances. Similarly, Aenova maintained its market position in the biopharmaceutical contract manufacturing market after the acquisition of Haupt Pharma AG, and by selling its Temmler business in 2015. Both, biopharmaceutical contract manufacturing companies – Fareva and Famar have successfully adopted an integration strategy of acquiring manufacturing facilities in Europe from large pharmaceutical companies.

Reinventing the European advanced therapies sector may fuel outsourcing activities to biopharmaceutical contract manufacturing players in the region. The next generation therapy market is driven by biological treatment options. These biologics demand more research and clinical trials, and hence, to reduce the cost, most research activities are outsourced to biopharmaceutical contract manufacturing players. The region is richly endowed with venture capitalists, which makes the availability of funding easier for biopharmaceutical contract manufacturing organizations. Potential margins for biopharmaceutical contract manufacturing companies are better in Europe as compared to the U.S. Factors noted by customers while approaching a biopharmaceutical contract manufacturing company are various. As per a NICE survey, a biopharmaceutical contract manufacturing company is selected based on location, quality of service, cGMP compliance, specific expertise in therapeutic area of focus, reputation and area of expertise, and infrastructure.

The top activity outsourced to biopharmaceutical contract manufacturing companies is analytical testing, followed by toxicity testing and fill/finish operations. Dominant outsourcing activities across the biopharmaceutical sector are restricted to services where a high degree of specialization may be required. While outsourcing to biopharmaceutical contract manufacturing companies can address a host of limitations, it comes with its own set of problems – protecting intellectual property rights, effectively handling cross-contamination issues, and complying with quality standards.

Rising focus on cost-effective biopharmaceutical contract manufacturing and the popularity of biosimilar added with the existence of patent cliff of blockbuster biologic drugs in the near future is expected to boost the growth of the biopharmaceutical contract manufacturing market. Big biopharmaceutical companies focusing on reduction in operating costs through the outsourcing of R&D and commercialization of biologic drugs to biopharmaceutical contract manufacturing companies could also increase the growth of the biopharmaceutical contract manufacturing market during the forecast period. However, complex manufacturing guidelines & regulatory processes, limited capacity for large-volume biopharmaceuticals, and high investments requirement to establish a biopharmaceutical contract manufacturing facility will continue to pose challenges to widespread adoption of outsourcing services in biopharmaceutical contract manufacturing market.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-2982 

Some of the key biopharmaceutical contract manufacturing companies analyzed in this report titled Biopharmaceutical contract manufacturing market include Lonza Group Ag, Baxter Healthcare Corporation, Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim GmbH, Patheon N.V., Rentschler Biotechnologie GmbH, Biomeva GmbH, ProBioGen AG, Cytovance Biologics Inc, Kbi Biopharma Inc, WuXi Biologics (Cayman) Inc., Abzena Plc, Vetter Pharma International GmbH, Sandoz International GmbH, Catalent Inc, and AbbVie Contract Manufacturing.

Knee Reconstruction Market to Register Substantial Expansion by 2022

Knee reconstruction is a surgical procedure that includes the relocation of ACL or anterior cruciate ligament which stabilizes the knee. In case of tear of this major knee component, it might cause the knee to give up during any kind of physical movement. Aging population is rising which experiences knee problems such as osteoarthritis or even rheumatoid arthritis. This has triggered the demand for knee reconstruction on a significant scale. The technological advancements in medical science has introduced minimally invasive techniques which have enhanced the knee reconstruction procedure with increased precision, reduced complications, reduced time of surgery and enhanced accuracy. Various knee reconstruction devices are available, such as cementless implants, partial implants, cemented implants and revision implants which are widely applied in knee reconstruction surgeries. The improvisation and innovation of tools for knee surgeries have increased the demand for knee reconstruction surgeries, thereby showing a positive influence over the global knee reconstruction devices market.

The global knee reconstruction devices market is expected to grow at a robust CAGR during the assessment period 2017 to 2022, and is anticipated to be valued at US$9.4 Bn by 2022 end.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4878

6 Forecast Highlights on Global Knee Reconstruction Devices Market

• North America region poised to dominate the global knee reconstruction devices market as it reflects high lucrativeness for the market growth during the 2017-2022 period and is expected to grow at a CAGR of 6.1%. Asia Pacific excluding Japan (APEJ) shows high potential of growth in the global knee reconstruction devices market
• Cementless implants and partial implants segments by product type grow at a similar growth rate, however, cementless implants segment possesses high market share as of 2017 as compared to partial implants segment
• Cemented implants by product type dominate the global market with respect to growth rate as well as market share by revenue throughout the 2017-2022 period and this segment is also expected to experience a high gain in the BPS the 2022 end. Cemented implants segment is anticipated to reflect a robust CAGR of 6.4%
• Orthopaedic clinics segment by end user reflect highest growth rate during the period of assessment 2017-2022 and is growing at a huge CAGR of 7.1%
• Hospitals segment by end user dominate the global market in terms of revenue, however, compared to orthopaedic clinics and ASCs segments, show low growth rate
• Trauma segment by indication is poised to be the fastest growing segment and reflects a CAGR of 6.5% during the assessment period. Osteoarthritis segment by indication dominates the market with respect to higher revenue share in 2017 and is more likely to continue dominating the market in the coming years

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-4878

The report has also profiled key leading players in the global knee reconstruction devices market, which would remain active through 2022. These include players like Tornier Inc., Japan Medical Dynamic Marketing, DJO Global, Exactech Inc., Arthrex Inc., United Orthopedic Corporation, Corin, Smith & Nephew, DePuy Synthes, Stryker Corporation and Zimmer, Inc.

Soft Tissue Repair Market is Set to Experience Revolutionary Growth by 2022

A new report by Future Market Insights (FMI) anticipates the global soft tissue repair market to exhibit a steady 5.5% CAGR throughout the forecast period (2017-2022). The global market for soft tissue repair is expected to account for over US$ 15,000 Mn revenues by 2022-end.

Advancements in Products such as Bioabsorbable Soft Tissue Screws to Propel Growth of the Market

A number of technological advancements and innovations have been observed in orthopedic connective tissue repair procedures. Novel advances, for instance – the innovative surgical techniques, are being made in the procedures associated with anterior cruciate ligament (ACL) reconstruction, in a bid to make the process more effective. Global leaders, including Zimmer Biomet and NORAKER, have been developing new bioabsorbable soft tissue screws over the past few years. Leading market players have also been focusing on development of the mesh with biological products, which would act as a replacement for human allograft. An example of this is development of EZ Derm by MoInlycke Health Care, utilized as dressing for wounds using wires and pins independently, or together, with various other internal fixation devices. These devices are utilized for surgeries pertaining to hip replacement and spine.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4931

People across the globe are becoming aware of development, promotion, and commercialization of the advanced platelet-rich plasma devices, used for musculoskeletal disorders. In addition, there is a surge in awareness about skeletally immature patients to have a high risk of tear in the connective tissue and ligaments. These factors might positively impact global demand for soft tissue repair in the near future.

Sports-related Injuries- A Major Factor Driving the Market Growth

A major factor affecting demand for soft tissue repair is injuries related to sports. Athletes usually suffer from ACL tear during the game, or while performing other physical activities. Moreover, increasing aging population is also expected to play an imperative role in growth of the market. With aging, substantial changes are observed in skeletal and neuromuscular systems, which in turn leads towards ACL tear, weak ligaments and arthritis. Prevalence of obesity in geriatric population is directly increasing risk of degenerative bone diseases, such as osteoporosis and osteoarthritis. The aforementioned factors are further expected to increase demand for soft tissue repair procedures.

In contrast, high prices associated with soft tissue repair procedures, lack of awareness in population across underdeveloped and remote regions, and unfavorable reimbursement policies are factors which will impede demand for soft tissue repair procedures in the near future.

APEJ to Witness a Significant Expansion in the Market

The soft tissue repair market in Asia-Pacific excluding Japan (APEJ) is expected to witness a significant growth, with revenues poised to surpass US$ 3,000 Mn by 2022-end. Growth of the market in APEJ can be primarily attributed to increasing purchasing power of population, and rising prevalence of musculoskeletal disorders in countries such as India and China. In addition, North America is expected to remain the most attractive market for soft tissue repair, owing to the hike in healthcare expenditure in this region.

Based on product, sales of laparoscopic instruments, and synthetic mesh are expected to collectively account for over one-third revenue share of the market during the forecast period. Sales of synthetic mesh and laparoscopic instruments will register similar CAGRs through 2022.

Orthopedic Application of Soft Tissue repair to Account for Largest Revenue Share

Orthopedic application of soft tissue repair are expected to account for the largest revenue share of the market during 2017 to 2022, followed by skin repair application. In addition, revenues from orthopedic and skin repair application of soft tissue repair are expected to collectively account for over US$ 7,000 Mn by 2022-end.

Accounting for around two-third revenue share of the market, hospitals are expected to remain the most lucrative end-users in the global market for soft tissue repair. Revenues from hospitals in the market are expected to reach approximately US$ 10,000 Mn by 2022-end.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/reports/sample/REP-GB-4931

Key players profiled by the FMI’s report, who are actively operating in the global soft tissue repair market, include Wright Medical Group N.V., Integra LifeScience Corporation, Medtronic Plc., CONMED Corporation, C. R. Bard, Inc., Braun Melsungen AG, Smith & Nephew, DePuy Synthes, Stryker Corporation, Zimmer Biomet Holdings, Inc., and Arthrex Inc.

Herbal Medicinal Products Market to Record Sturdy Growth by 2027

The worldwide herbal medicinal products market is foreseen to develop reliably. This market is required to indicate noteworthy development in the Asia Pacific locale amid the estimate time frame i.e., in the vicinity of 2017 and 2027. For the further improvement of the market, makers need to put more in innovative work of the products and increment their item portfolio. Association and mergers are similarly essential for makers to manage in the worldwide herbal medicinal products market. These two components are relied upon to build the item portfolio as well as have the capacity to enable organizations to accomplish a solid market nearness over the globe. According to a recent report by Future Market Insights (FMI), with hearty CAGR of 7.6% amid the anticipated period, the worldwide market for herbal medicinal products is required to be esteemed at somewhat more than US$ 130 Bn in 2017.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2722

Increase in Demand for Green Label Products to Propel the Global Market

Expanding customer interest for green label products is bringing about makers moving from specialty dispersion channels to standard mass retailers. In addition, general store chains are additionally extending item runs on their racks, which has brought about a sharp increment in shares of the herbal supplement items in the gone by years. High reception and fare of KAMPO solutions in Japan region is one of the explanation behind boosting the worldwide herbal medicinal products market. KAMPO solution is extremely mainstream and is broadly utilized as a part of Japan, which depends on conventional Chinese pharmaceutical in any case, altered as per the Japanese culture. Moreover, it is likewise received in Taiwan too with some alteration and sent out toward the Western locales. As indicated by the market review by WHO around 30% or more of the aggregate OTC medications that are for sale in Japan was readied utilizing organic products.

Ayurvedic Pharmaceuticals Segment to Account for Major Amount of Shares in the Market

Ayurvedic pharmaceuticals is required to be one of the most flourishing among all item sort fragment of herbal medicinal products market, including attractive index figure of 2.3. Besides, with over 55% income share, the Ayurvedic pharmaceuticals portion is probably going to be evaluated  to be around US$ 75 bn in year 2017, extending at a CAGR of 6.6%. In regions, for example, North America, the herbal meds products are viewed as/sold as dietary supplements or nutraceuticals with wellbeing claims, which is pre-affirmed by Food and Drug Administration (FDA) under Dietary Supplements Health and Education Act. The FDA controls for these products are less stringent when contrasted with the customary solutions. Accordingly, the great direction for herbals drugs especially in North America helps the improvement of the worldwide herbal prescriptions market. Expanding geriatric populace is another factor which is boosting the development of the worldwide herbal medicinal products market. The maturing populace in the nations, for example, Brazil and Mexico is equivalent to the European and North America nations. This populace utilize dietary supplements which powers the offer of herbal medicinal products.

Rise in Number of Patients Suffering from Join Pain to Fuel the Market Demand

Expanding number of individuals experiencing joint pain inclines toward normal strategies for treatment to remember the side effects caused by joint pain. Growing inclination towards regular cures gives great development chances to the players in basic oil industry sooner rather than later. Expanding interest for herbal supplements products is making open doors for players in the worldwide herbal supplements market to grow in various area through sending out their products Homeopathy has turned into an inexorably imperative component in the worldwide medicinal framework. The homeopathic cures have accomplished driving positions in various OTC classes. The online deals or web based business circulation channel has seen emotional increment in herbal medicinal products market in recent few years.

Read Comprehensive Overview with Methodology of Report  @ https://www.futuremarketinsights.com/askus/rep-gb-2722

Sanofi-Aventis Healthcare PTY Ltd., Nutraceutical Corporation, Himalaya Global Holdings Ltd., Integria Healthcare, Young Living Essential Oils, Blackmores Limited, Arkopharma SA, STADA Arzneimittel AG, Boiron Group, and MOUNTAIN ROSE HERBS are some of the key players reigning the global market.

Allergy Diagnostics Market Rugged Expansion Foreseen by 2022

The global market for allergy diagnostics has been forecast to account for over US$ 4,000 Mn revenues by 2022-end, according to a latest research by Future Market Insights (FMI). The report further projects the market to exhibit an impressive CAGR of nearly 10% through 2022.

Urban & Western Lifestyles Leading toward Susceptibility to Allergic Disorders

A key theory gaining popularity in the global allergy diagnostics market is “hygiene hypothesis”. According to the hypothesis, absence of exposure to microorganisms & infectious agents in early childhood is likely to increase proneness of individuals to allergies, refraining the essential development of their immune system. The urban and western lifestyles of people have made them more susceptible to allergic diseases, as they have limited exposure to infectious agents during their childhood. Genetic factors and surging pollution levels are some major factors adding to the prevalence of allergic disorders. Introduction of advanced technologies and rapid growth in healthcare expenditure will play a major role in reducing impact of aforementioned factors. However, stricter government policies and regulations associated with drugs and therapies, and huge capital investment required for development of these drugs will remain as challenges for organisations operating in the market.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-4959

Leading Market Players focusing on Revolutionizing Healthcare Sector

Several governments around the world are supporting development of vaccines and therapies associated with allergic diseases through investments in research and development activities related to allergy diagnostics. In addition, leading market players are focusing on revolutionizing and optimization of healthcare sector. A key strategy adopted by these players is collaboration with predominant organizations. For example – in 2016, Quest Diagnostics collaborated with AncestryDNA, in a bid to cater soaring demand from consumers for genetic tests, given the genetics’ role in development of allergies. The surge in incidences of allergies such as asthma, allergic rhinitis, sinusitis, and food allergy, are driving demand for their diagnostics over the recent past. According to WHO, number of patients with asthma is likely to surpass 400 Mn by 2025-end. Moreover, statistics offered by American Academy of Allergy, Asthma, & Immunology depict around 15% of population worldwide to be suffering from allergic rhinitis worldwide annually.

Key Research Findings from FMI’s Report on Global Allergy Diagnostics Market

• Diagnostic laboratories will remain sought-after among patients for allergy diagnostics, with revenues projected to account for over 40% revenue share of the market in 2017. However, diagnostic laboratories will observe a decline in their market share between 2017 and 2022.
• The allergy diagnostics market in Asia-Pacific excluding Japan (APEJ) is projected to expand at a relatively higher CAGR through 2022. This can be mainly attributed to a relatively higher prevalence of allergic disorders, especially in growing older population in the region, along with rising disposable income, and surging developments in healthcare infrastructures. In addition the market in Japan is estimated to create an absolute $ opportunity of approximately US$ 150 Mn between 2017 and 2022.
• Based on allergen type, revenues from diagnosis of allergies caused by food allergens are estimated to reach nearly US$ 1,300 Mn by 2022-end.
• On the basis of test type, in-vivo tests are expected to remain comparative less lucrative than in-vitro test for allergy diagnostics throughout the forecast period.
• Based on Product type, sales of consumables and instruments are projected to register the fastest expansion in the market through 2022. In terms of revenues, instruments are estimated to account for a comparatively larger market share than consumables over the forecast period. In contrast, services will account for the lowest share of the market, in terms of revenues, through 2022.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-4959

FMI’s report has offered a list of key players that are actively operating in the allergy diagnostics market, which include Thermo Fisher Scientific, Inc., Siemens Healthcare, Danaher Corporation, Hitachi Chemical Co., Ltd., HOB Biotech Group Co, Biomérieux SA, Stallergenes Greer, R-Biopharm AG, Hycor Biomedical Inc., and Lincoln Diagnostics, Inc.

Multiplex Biomarker Imaging Market Attractive Market Opportunities in the by 2027

A new report published by Future Market Insights titled “Multiplex Biomarker Imaging Market: Global Industry Analysis (2012 – 2016) and Opportunity Assessment (2017 – 2027)” studies the performance of the global multiplex biomarker imaging market over a ten year assessment period from 2017 to 2027. The report presents the value forecast of the global multiplex biomarker imaging market and provides key insights into the factors driving market growth as well as the factors restricting market growth. The estimates point to a revenue growth from about US$ 270 Mn in 2017 to nearly US$ 843 Mn by 2027 end, resulting in a CAGR of 12% over the forecast period.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3526

Global Multiplex Biomarker Imaging Market: Segmentation and Forecast

The global multiplex biomarker imaging market is segmented on the basis of component type, imaging technique, application and end-user.

• The instrument segment is estimated to be valued at US$ 200.6 Mn in the year 2017 and is poised to reach a value of US$ 620.4 Mn at the end of the year 2027 and exhibit a CAGR of 12% during the period of assessment.
• The software segment is estimated to be valued at US$ 41.2 Mn in the year 2017 and is slated to reach a value of US$ 133.2 Mn at the end of the year 2027 and exhibit a CAGR of 12.5% during the period of assessment.
• The IHC Assay segment is estimated to be valued at US$ 177.9 Mn in the year 2017 and is slated to reach a value of US$ 557.4 Mn at the end of the year 2027 and exhibit a CAGR of 12.1% during the period of assessment.
• The FISH Assay segment is estimated to be valued at US$ 59.4 Mn in the year 2017 and is poised to reach a value of US$ 179.4 Mn at the end of the year 2027 and exhibit a CAGR of 11.7% during the period of assessment.
• The research segment is estimated to be valued at US$ 238.6 Mn in the year 2017 and is poised to reach a value of US$ 740.5 Mn at the end of the year 2027 and exhibit a CAGR of 12% during the period of assessment.
• The translational laboratories segment is estimated to be valued at US$ 4 Mn in the year 2017 and is slated to touch a value of US$ 418.2 Mn at the end of the year 2027 and exhibit a CAGR of 12.8% during the period of assessment.

Global Multiplex Biomarker Imaging Market: Regional Forecast

Future Market Insights tracks the performance of the global multiplex biomarker imaging market across the key geographies of North America, Latin America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan, and Middle East and Africa. As per the forecast of Future Market Insights, the North America multiplex biomarker imaging market is estimated to be valued at US$ 152.4 Mn in the year 2017 and is slated to touch a value of US$ 501.4 Mn at the end of the year 2027 and exhibit a CAGR of 12.6% during the assessment period. The Western Europe multiplex biomarker imaging market is estimated to be valued at US$ 64.7 Mn in the year 2017 and is poised to touch a value of US$ 208.6 Mn at the end of the year 2027 and exhibit a CAGR of 12.4% during the period of assessment.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-3526

Global Multiplex Biomarker Imaging Market: Vendor Insights

The report has included some of the key players operating in the global multiplex biomarker imaging market such as Perkin Elmer, Inc., Bio-rad Laboratories Inc., Thermo Fisher Scientific, Inc., Abcam plc., Merck KGaA, Illumina Inc., Leica Biosystems Nussloch GmbH, Ventana Medical Systems, Inc., Aushon BioSystems Ltd., MicroConstants, Inc. and ToposNomos Ltd. Leading manufacturer of Multiplex Biomarker Imaging are focusing on collaborations with laboratories and biopharmaceutical companies in order to expand sales presence. Other companies are focusing on targeting technologically advanced emerging economies such as Asia Pacific region with availability of sufficient capital base and skilled labour.

Animal Healthcare Market Healthy Pace throughout the Forecast during 2017 - 2027

According to a recently compiled study by Future Market Insights, the global animal model market will reflect an impressive CAGR through the forecast period, 2017 to 2026. Revenues from the global market for animal model are poised to surpass US$ 2,200 Mn by 2026-end.

Leveraging Animal Models offers Better Understanding of Different Diseases

Animals and human beings share a common biological as well as physiological structure. Animals possess shorter life cycle, however they have high genotype resemblance. It is simple and easy to control the animal environment as compared to the human beings. The animal models are increasingly being used in the biomedical research that helps to develop new treatment methods for various diseases. Leveraging animal models offers a better understanding of different diseases, along with the efficacy of drugs with regard to the diseases. Owing to these factors, demand for animal models has been witnessing a significant surge in the healthcare sector. Alternatives such as cell cultures, tissue cultures, and computer models are also available, however animal models are more preferred owing to the complexity of the living systems. This further makes animal models an effective choice for biomedical research.

To Learn More about This Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3141 

Development of animal models, which are more predictive in being effective is an iterative process. However, progress is being made, with researchers applying new experimental approaches to elucidate the biology of specific diseases for the creating of new and efficient animal models. During the development of new drugs dedicated to complex diseases, researchers are being well advised for testing drugs in multiple animal models as well as in mouse strains with different genetic backgrounds. Researchers are also focusing on employing translational efficacy or pharmacodynamic biomarkers for linking efficacy observed in clinical results with pre-clinical analyses.

Key Takeaways from FMI’s Report on Global Animal Model Market

• North America is expected to remain the largest and fastest expanding market for animal model, with revenues estimated to surpass US$ 800 Mn by 2026-end. Between animal model markets in Asia-Pacific and Europe, the former will account for relatively larger revenue share, whereas the latter will expand at a comparatively higher CAGR through 2026. Although the market in South Korea will account for the lowest market revenue share, revenues are projected to expand at a relatively higher CAGR than those from the markets in Latin America and Middle East & Africa (MEA) through 2026.
• On the basis of species, revenues from rats and mice are projected to account for over two-fifth share of the market by 2026-end. Revenues from use of rats in animal models will expand at the highest CAGR in the market through 2026. In addition, revenues from use of cats and monkeys in animal models will rise at a nearly equal CAGR through 2026. Dogs and pigs are expected to remain the least lucrative species used in animal models during the forecast period.
• Contract research organizations (CROs) and biotechnology companies are anticipated to remain the fast expanding end-users of animal models. Revenues from these two end-users are collectively forecast to surpass US$ 850 Mn by 2026-end. In terms of revenues, academic & research institutions and pharmaceutical companies will continue to be dominant end-users in the global animal model market.
• Basic and applied research application of animal model will continue to register the fastest expansion through 2026. However, drug discovery/development will remain the most lucrative application of animal model.
• Key companies actively contributing to growth of the global animal model market include Transposagen Biopharmaceuticals, Inc., Envigo CRS SA, Crown Bioscience, Inc., Eurofins Scientific SE, Genoway SA, Taconic Biosciences, Inc., Trans Genic Inc, The Jackson Laboratory, Horizon Discovery Group plc, and Charles River Laboratories International, Inc.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-3141 

Molecular Imaging Market Likely to Emerge over a Period of 2017 - 2027

The global molecular imaging market is expected to witness robust growth during the forecast period. This growth is expected to be primarily driven by increasing demand for advanced integrated molecular imaging devices such as PET-CT and PET-MR from hospitals and diagnostics imaging centres. “Molecular Imaging Market: Global Industry Analysis (2012 –2016) and Opportunity Assessment (2017 – 2027),” is the newly published report by Future Market Insights which focuses on the key strategies such as acquisitions, mergers, expansion and product launchesadopted by the manufacturers and integrators in this market for technology transfer and to increase consumer base in different geographies. The global molecular imaging market is projected to register a CAGR of 7.5% in terms of value during the forecast period i.e. 2017–2027 and to be valued at US$ 6,445.8 Mn by 2027.

A Sample of this Report is Available upon Request @ https://www.futuremarketinsights.com/reports/sample/rep-gb-724

Global Molecular Imaging Market: Drivers

Following are some of the factors which are contributing in the growth of the global molecular imaging market throughout the forecasted period.

• Advancements in the molecular imaging
• Favorable reimbursement for molecular imaging and treatment
• Increasing demand for molecular imaging and diagnosis
• Increasing incidences of ageing population’s MRI diagnostics
• Expanding application of integrated PET-CT and PET-MR devices
• Favorable government policies for startup companies
• Increasing Strategic Collaborations among key players
• Increasing reliance of physicians and radiologists on the technology

Global Molecular Imaging Market: Forecast by Modality Type

On the basis of modality type, the global molecular imaging market is segmented into- Positron Emission Tomography (PET), Positron Emission Tomography- Computed Tomography (PET-CT),

Positron Emission Tomography-Magnetic Resonance (PET-MR), Single Photon Emission, Computed Tomography (SPECT), Magnetic Resonance Spectroscopy, Molecular Ultrasound Imaging Software. The SPECT segment of modality type accounted for 23.3%market share in 2016, which is expected to decrease to 22.7% by 2027end. This segment is expected to accounts for large revenue contributionto the global molecular imaging market as compared to other segmentsover the forecast period. On the other hand PET-CT molecular imaging segment is expected to witness a significant rise in revenue share over the forecast period, owing to increasing awareness about the advantages of PET-CT integrated devices compared to stand alone molecular imaging devices.

Global Molecular Imaging Market: Forecast by End User

This segment consists of hospital, ambulatory surgical centre, and diagnostic imaging centre. Hospital segment is sub-segmented into 500 + beds, 200-499 beds, and less than 200 Beds.   Hospital segment dominated the global molecular imaging market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. Hospitals segment is expected to be the most lucrative among all end users, with attractiveness index of 1.8. This segment is expected to grab 58% revenue share in 2027.

Global Molecular Imaging Market: Forecast by Application

Application segment includes cardiology, oncology, gastrointestinal disorders, neurology disordersand others. In terms of value, oncology is the largest segment and is likely to be valued US$ 2,391.7 Mn in 2027. However, in terms of CAGR, neurological disorders segment is ahead with 8.4% Compound Annual Growth Rate at the end of the projected period. By market share index, this segment is expected to be the second largest in the global molecular imaging market.

Global Molecular Imaging Market: Forecast by Region

This report has covered seven regions such as North America, Latin America, Eastern Europe, Western Europe, APEJ, Japan, and MEA. APEJrepresents the most lucrative market, followed by MEA andNorth America. The APEJ molecular imaging market revenue is expected to expand at a significant CAGR of 8.6% in terms of value over the forecast period. The hospitals and diagnostics imaging centres in APEJ are expectedto witness comparatively significant growthdue to increasingdemand of advanced molecular imaging and developing medicalinfrastructure in the region.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-724

Global Molecular Imaging Market: Key Players

These are some of the key players in the global molecular imaging market- Hermes Medical Solutions, MIM Software Inc., Bruker Corporation, GE Company, Fujifilm Holdings Corp., Siemens AG, Koninklijke Philips N.V., Toshiba Medical System Corp., Hitachi Medical Corp.,Medisco Ltd., Positron Corporation, Esaote SpA, Carestream Health, Inc., Mirada Medical Limited.